chen, chenyan – page 3 – eisai china lnc.-威尼斯人888

sahne medical spray is the first otc drug spray-type lotion containing heparinoid

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that it has launched sahne® medical spray and sahne® medical cream (both are category-2 otc drugs, “sahne medical”) on august 25, 2020 at pharmacies and drugstores throughout japan, as a new product of the sahne brand lineup which has been a favored hand care for generations.

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) and msd k.k. (headquarters: tokyo, president: jannie oothuizen, “msd”), a subsidiary of merck & co., inc., kenilworth, n.j., u.s.a., announced today that eisai has submitted an application in japan for the additional indication of treatment of unresectable thymic carcinoma for multiple receptor tyrosine kinase inhibitor lenvima ® (generic name: lenvatinib mesylate). in june 2020, lenvima received orphan drug designation in japan for unresectable thymic carcinoma.

allm inc. (shibuya-ku, tokyo, president: teppei sakano, hereafter allm), tokyo medical and dental university (bunkyo-ku, tokyo, president: yujiro tanaka) and eisai co., ltd. (headquarters: bunkyo-ku, tokyo, ceo: haruo naito, hereafter eisai) announced that their jointly submitted study and development project has been selected by the japan agency for medical research and development (amed) for its publicly advertised 2020 “field of support for experimental study on medical devices and systems that contribute to measures against viruses and other infectious diseases” as part of its “technology development project for measures against viruses and other infectious diseases “, and that allm has entered into an industry-academia-government joint research agreement with tokyo medical and dental university and eisai respectively.

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that it has entered into an industry-academia-government joint research agreement with four universities in japan concerning the “industrialization of japan-originated toll-like receptor research by academia-industry collaborating all-japan system: creation of new drug for sle treatment”, which is a research project with eisai as the representative research organization. this joint research project was selected by the japan agency for medical research and development (amed) for its cyclic innovation for clinical empowerment (cicle) grant program. in this project, eisai aims at creating a japan-originated therapeutic drug for systemic lupus erythematosus (sle) through industry-academia-government collaboration, using its in-house discovered new oral toll-like receptor (tlr) 7/8 inhibitor e6742.